Top ▲

Interleukin-2 receptor subunit α

Click here for help

Target id: 1695

Nomenclature: Interleukin-2 receptor subunit α

Family: IL-2 receptor family

Contents:

Quaternary Structure: Complexes
Interleukin-2 receptor
Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 272 10p15.1 IL2RA interleukin 2 receptor subunit alpha
Mouse 1 268 2 8.91 cM Il2ra interleukin 2 receptor, alpha chain
Rat 1 267 17q12.2 Il2ra interleukin 2 receptor subunit alpha
Previous and Unofficial Names Click here for help
CD25 | TAC antigen | IL2RAC | IL-2R alpha chain | Ly-43 | interleukin 2 receptor
Database Links Click here for help
Alphafold P01589 (Hs), P01590 (Mm), P26897 (Rn)
ChEMBL Target CHEMBL1778 (Hs), CHEMBL3287 (Mm)
DrugBank Target P01589 (Hs)
Ensembl Gene ENSG00000134460 (Hs), ENSMUSG00000026770 (Mm), ENSRNOG00000047647 (Rn)
Entrez Gene 3559 (Hs), 16184 (Mm), 25704 (Rn)
Human Protein Atlas ENSG00000134460 (Hs)
KEGG Gene hsa:3559 (Hs), mmu:16184 (Mm), rno:25704 (Rn)
OMIM 147730 (Hs)
Pharos P01589 (Hs)
UniProtKB P01589 (Hs), P01590 (Mm), P26897 (Rn)
Wikipedia IL2RA (Hs)

Download all structure-activity data for this target as a CSV file go icon to follow link

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
daclizumab Peptide Approved drug Primary target of this compound Immunopharmacology Ligand Hs Binding >8.0 pKd 1
⤷ pKd >8.0 (Kd <1x10-8 M) [1]
basiliximab Peptide Approved drug Immunopharmacology Ligand Hs Binding - -
⤷
Immunopharmacology Comments
IL2RA is a ligand binding component of the IL-2R complex. This subunit is the molecular target of the approved biologics daclizumab (including daclizumab beta) and basiliximab. Another anti-CD25 mAb, inolimomab, has received orphan drug designation from the EMA, for the treatment of graft-versus-host disease. Phase 3 findings for this drug and indication are reported in [2], the major conclusion being that the primary end point for the trial was not met (no statistical difference between the inolimomab and normal standard of care arms of the study).
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 3 GO processes
GO:0006954 inflammatory response IBA
click arrow to show/hide IEA associations
GO:0002437 inflammatory response to antigenic stimulus IEA
GO:0050728 negative regulation of inflammatory response IEA
Immuno Process:  Immune regulation
GO Annotations:  Associated to 8 GO processes
GO:0002664 regulation of T cell tolerance induction IMP
click arrow to show/hide IEA associations
GO:0006924 activation-induced cell death of T cells IEA
GO:0042104 positive regulation of activated T cell proliferation IEA
GO:0042130 negative regulation of T cell proliferation IEA
GO:0045582 positive regulation of T cell differentiation IEA
GO:0046013 regulation of T cell homeostatic proliferation IEA
GO:0050728 negative regulation of inflammatory response IEA
GO:2000561 regulation of CD4-positive, alpha-beta T cell proliferation IEA
Immuno Process:  Immune system development
GO Annotations:  Associated to 2 GO processes
GO:0002664 regulation of T cell tolerance induction IMP
click arrow to show/hide IEA associations
GO:0045582 positive regulation of T cell differentiation IEA
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 1 GO processes
GO:0004911 interleukin-2 receptor activity TAS
Immuno Process:  T cell (activation)
GO Annotations:  Associated to 7 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0006924 activation-induced cell death of T cells IEA
GO:0042104 positive regulation of activated T cell proliferation IEA
GO:0042130 negative regulation of T cell proliferation IEA
GO:0045582 positive regulation of T cell differentiation IEA
GO:0046013 regulation of T cell homeostatic proliferation IEA
GO:0050798 activated T cell proliferation IEA
GO:2000561 regulation of CD4-positive, alpha-beta T cell proliferation IEA
Immuno Process:  Chemotaxis & migration
GO Annotations:  Associated to 3 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0042104 positive regulation of activated T cell proliferation IEA
GO:0042130 negative regulation of T cell proliferation IEA
GO:0045582 positive regulation of T cell differentiation IEA
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 6 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0042104 positive regulation of activated T cell proliferation IEA
GO:0042130 negative regulation of T cell proliferation IEA
GO:0045582 positive regulation of T cell differentiation IEA
GO:0046013 regulation of T cell homeostatic proliferation IEA
GO:0050798 activated T cell proliferation IEA
GO:2000561 regulation of CD4-positive, alpha-beta T cell proliferation IEA

References

Show »

1. Queen CL, Schneider WP, Selick HE. (1997) Genetic engineering; complementarity zones. Patent number: US5693761. Assignee: Protein Design Labs, Inc.. Priority date: 28/12/1988. Publication date: 02/12/1997.

2. Socié G, Vigouroux S, Yakoub-Agha I, Bay JO, Fürst S, Bilger K, Suarez F, Michallet M, Bron D, Gard P et al.. (2017) A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood, 129 (5): 643-649. [PMID:27899357]

How to cite this page

IL-2 receptor family: Interleukin-2 receptor subunit α. Last modified on 27/10/2017. Accessed on 10/06/2023. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=1695.